<DOC>
	<DOCNO>NCT02739165</DOCNO>
	<brief_summary>The purpose study assess efficacy safety intravenous drip infusion ART-123 patient acute exacerbation idiopathic pulmonary fibrosis ( IPF ) multicenter , double-blind , randomize , placebo-controlled , parallel group comparison study , confirm superiority placebo survival rate Day 90 primary endpoint .</brief_summary>
	<brief_title>Clinical Study ART-123 Treatment Acute Exacerbation Idiopathic Pulmonary Fibrosis</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Pulmonary Fibrosis</mesh_term>
	<mesh_term>Idiopathic Pulmonary Fibrosis</mesh_term>
	<mesh_term>Idiopathic Interstitial Pneumonias</mesh_term>
	<criteria>Main Patients diagnose IPF meet criterion ( 1 ) ( 4 ) course IPF ( 1 ) Unexplained development worsen dyspnea within 1 month course IPF ( 2 ) Finding new , bilateral ground glass opacity and/or consolidation HRCT ( 3 ) No apparent Pulmonary infection , pneumothorax , malignant tumor , pulmonary embolism , leave heart failure ( 4 ) A decrease* PaO2 ≥10 mmHg SpO2 ≥4 % condition compare level previous measurement ( * ) In case PaO2 SpO2 test value condition available , patient P/F ratio ≤300 current episode acute exacerbation consider meet criterion ( 4 ) Aged 40 year old old 85 year time inform consent either sex Main Have intracranial hemorrhage , pulmonary hemorrhage , gastrointestinal bleeding ( continued hematemesis , bloody discharge , gastrointestinal ulcerinduced hemorrhage ) Have history cerebrovascular disorder ( e.g. , cerebral hemorrhage cerebral infarction ) within 52 week ( 364 day ) inform consent Patients completion hemostatic treatment confirm undergoing surgery central nervous system trauma Have high risk fatal lifethreatening hemorrhage Patients malignant tumor Have acute exacerbation attributable drug induce pulmonary disorder , surgery malignant tumor , chemotherapy , radiation therapy Have acute exacerbation due thoracic surgical procedure ( include thoracoscopic lung biopsy ) Have history acute exacerbation IPF Receiving mechanical ventilation intratracheal intubation Patients pregnant nursing , may pregnant Patients platelet count le 50,000/uL time enrollment Patients severe renal ( serum Cr : ≥4 mg/dL ) hepatic ( AST/ALT : ≥500 IU/L TBil : ≥10 mg/dL ) dysfunction Have administer commercially available thrombomodulin alfa ( recombinant ) ( Recomodulin® Intravenous Injection 12800 ) within 30 day start investigational product administration Have history hypersensitivity investigational product</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Acute exacerbation</keyword>
	<keyword>Idiopathic pulmonary fibrosis</keyword>
	<keyword>Recombinant human soluble thrombomodulin</keyword>
	<keyword>ART-123</keyword>
</DOC>